BCR and diffuse large B-cell lymphoma: Sotrastaurin selectively inhibited the growth of CD79 mutant BCR-subtypes of ABC-DLBCL in vitro and in vivo whereas the presence of CARD11 mutations resulted in resistance to the inhibitor [253].